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Tumor formation is the result of molecular al­
terations involving cellular regulators (Hanahan 
and Weinberg, 2011) as well as the ability of 
tumor cells to affect the tumor microenviron­
ment by smoldering inflammation (de Visser 
et al., 2006; Mantovani et al., 2008) or even taking 
advantage of inflammation to grow and metas­
tasize (Zitvogel et al., 2006; Grivennikov et al., 
2010). Indeed, targeted therapies aimed to in­
hibit molecular alterations in tumor cells even 
though inducing antitumor responses have 
improved overall survival only slightly, indicat­
ing that antitumor strategies comprehensive of 
drugs targeting molecular as well as microen­
vironment alterations might be more effective 
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Tumor-infiltrating immune cells can be conditioned by molecules released within the  
microenvironment to thwart antitumor immune responses, thereby facilitating tumor 
growth. Among immune cells, neutrophils play an important protumorigenic role by favor-
ing neoangiogenesis and/or by suppressing antitumor immune responses. Tumor-derived 
oxysterols have recently been shown to favor tumor growth by inhibiting dendritic cell 
migration toward lymphoid organs. We report that tumor-derived oxysterols recruit pro-
tumor neutrophils in a liver X receptor (LXR)–independent, CXCR2-dependent manner, thus 
favoring tumor growth by promoting neoangiogenesis and immunosuppression. We demon-
strate that interfering with the oxysterol–CXCR2 axis delays tumor growth and prolongs 
the overall survival of tumor-bearing mice. These results identify an unanticipated pro-
tumor function of the oxysterol–CXCR2 axis and a possible target for cancer therapy.
© 2013 Raccosta et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
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Figure 1. Analysis of tumors releasing LXR ligands and quantification of hydroxycholesterols in cell supernatants by chemical ionization–MS 
and HPLC analysis. (A) Luciferase assay for LXR- activation by the indicated tumor CM. Each symbol corresponds to a single experiment, and the line 
represents the mean value (*, P < 0.05; **, P < 0.01; ***, P < 0.0001). RLA, relative luciferase activity. (B) Spectrum derived from 1 mM hydroxycholes-
terol mix solution (containing 22R, 22S, 25, 27, 19, 7, and 4-HC). The molecular mass for the mix of hydroxycholesterols is 402.67 kD. The collision 
JEM Vol. 210, No. 9 
Article
1713
(Vanneman and Dranoff, 2012). Tumor microenvironment is 
composed of various cell types, including tumor­associated 
macrophages endowed with phenotypes and functions of 
alternatively activated or M2 macrophages (i.e., expressing 
IL­10, TGF­, ARG1, and mannose receptor; Mantovani and 
Sica, 2010), which have been shown to promote tumor initia­
tion/formation through the induction of immune suppres­
sion, matrix remodeling, and angiogenesis (Murdoch et al., 
2008), and the heterogeneous CD11b+Gr1+ myeloid cells, 
also termed myeloid­derived suppressor cells, comprising im­
mature myeloid progenitors for neutrophils, monocytes, and 
DCs (Gabrilovich and Nagaraj, 2009). CD11b+Gr1+ myeloid 
cells are present in the tumor as well as in bone marrow, pe­
ripheral blood, and spleen of tumor­bearing mice (Bronte and 
Zanovello, 2005). In particular, the immature CD11b+Gr1+ 
bone marrow–derived cells, as well as the CD11bhighGr1high 
Ly6G+ neutrophils, have been recognized as playing an im­
portant protumorigenic role by promoting neoangiogenesis 
(Yang et al., 2004) through the release of MMP9 (Nozawa 
et al., 2006) and Bv8 (Shojaei et al., 2008), thus mediating re­
fractoriness to anti­VEGF therapy (Shojaei et al., 2007a). Neu­
trophils have also been shown to suppress antitumor immune 
responses (Fridlender et al., 2009; De Santo et al., 2010).
Several tumor­derived molecules induce immune sup­
pression by affecting tumor­infiltrating immune cells (Vesely 
et al., 2011). Some of these molecules are intermediate or 
final products of the cellular metabolism, such as kynurenine, 
which, alone or together with the depletion of tryptophan, 
has been reported to promote T cell anergy (Mellor et al., 
2003). Similarly, it has been shown that the increased metab­
olism of l­arginine by myeloid cells can result in the impair­
ment of lymphocyte responses to tumor cells (Bronte and 
Zanovello, 2005). Other metabolic pathways have recently 
emerged as protumorigenic. Products of lipid and cholesterol 
metabolism have been demonstrated to damage the function 
of DC both in mouse and in human tumor models. As an 
example, lipid­loaded DCs are not able to effectively stimu­
late allogeneic T cells or to present tumor­associated anti­
gens as the result of a reduced antigen processing capability 
(Herber et al., 2010).
Liver X receptor (LXR) ligands, also named oxysterols, are 
involved in cholesterol homeostasis (Repa and Mangelsdorf, 
2000) and in modulating immune responses (Bensinger and 
Tontonoz, 2008). The oxysterol 7,25­HC, which is unable 
to activate LXRs, has recently been involved in B cell migra­
tion to follicles of lymphoid organ through the engagement 
of EBI2 receptor (Hannedouche et al., 2011; Liu et al., 2011). 
We have recently shown that LXR ligands/oxysterols are re­
leased by cancer cells and inhibit CCR7 expression on ma­
turing DCs, therefore dampening DC migration to draining 
lymph nodes and antitumor immune responses (Villablanca 
et al., 2010). Indeed, tumor cells engineered to express the oxy­
sterol inactivating enzyme sulfotransferase 2B1b (SULT2B1b; 
Fuda et al., 2007), fail to activate LXRs in vitro and are de­
layed or rejected when infused in immunocompetent mice 
(Villablanca et al., 2010). Whether tumor­derived LXR ligands/
oxysterols are endowed with other protumorigenic functions, 
thus favoring the formation of hostile microenvironments for 
immune cells, remains elusive.
Here, we show that tumor­derived oxysterols contribute 
to recruit neutrophils in a CXCR2­dependent manner within 
tumor microenvironment, thus favoring neoangiogenesis 
and/or immunosuppression and tumor growth. Importantly, 
we show that oxysterol inactivation, as well as CXCR2 in­
activation, controls tumor growth, thus identifying a new 
protumor role of oxysterols and a new therapeutic target for 
cancer patients.
RESULTS
Functional inactivation of tumor-derived LXR ligands/
oxysterols associates with lower levels of CD11bhighGr1high 
myeloid cells infiltrating tumors
Several mouse tumors release LXR ligands, as evaluated by a 
luciferase­based assay measuring LXR activation (Fig. 1 A). 
However, the species of LXR ligands produced by these 
tumors, as well as their possible effects on tumor­infiltrating 
immune cells other than DCs (Villablanca et al., 2010), are 
not known.
To identify the hydroxycholesterol species released by tumor 
cells, we performed solid­phase extraction of conditioned me­
dium (CM) from the T cell lymphoma RMA and NIH­3T3 
cells, the latter being unable to activate LXR (unpublished 
data), followed by mass spectrometry (MS) analysis. Cholesterol 
oxidation products share a common fragmentation pattern 
product ion pathway is constituted by the following fragment ions: m/z 385 [M-H2O], m/z 367 [M+H-2H2O], and m/z 369 [M+3H-2H2O]. Results are repre-
sentative of one out of three experiments. (C) Spectra derived from RMA hydroxycholesterols extract. The same molecular ions m/z 385, m/z 369, and m/z 
367 were detected as in B. Results are representative of one out of three experiments. (D) The relative abundance of the three main fragmentation ions 
(m/z 385, m/z 369, and m/z 367) is expressed as arbitrary intensity units (A.U.) with respect to 1 mM mix solution of hydroxycholesterols. (E) The concen-
tration of hydroxycholesterols with respect to ml of media (µmol/ml) is reported. Results (D and E) are representative of three different experiments 
(mean ± SEM). *, P < 0.05 versus medium; **, P < 0.01 versus NIH-3T3–CM. (F and G) HPLC chromatograms of seven single hydroxycholesterol standards 
(F) and of hydroxycholesterols from RMA-CM (G). Two main hydroxysterols are identified on the basis of the retention time: the 22-HC and 27-HC in a 
ratio of 4:1. (H) qRT-PCR for Cyp11a1, Cyp27a1, and Ch25h transcripts expression in RMA relative to NIH-3T3. Results are representative of two experi-
ments (mean ± SEM). *, P < 0.05; ***, P < 0.0001. (I and J) CM from human melanomas (I), and lung and kidney (J) tumors after a few in vitro passages  
(3–4 passages) were collected and tested for the presence of LXR ligands by LXR luciferase-based reporter assay. Each symbol corresponds to a single 
tumor CM tested and the line represents the mean value. **, P < 0.01; ***, P < 0.0001. (K) qRT-PCR analysis for Abcg1 and Srebp-1c mRNA expression in 
myeloid cells from bone marrow of wild-type (WT), RMA-Mock–, and RMA-SULT2B1b–bearing mice (n = 3; mean ± SEM). *, P < 0.05. Results are repre-
sentative of three independent experiments.
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in agreement with the presence of hydroxycholesterols in the 
fetal calf serum used to supplement the culture media (Pie 
and Seillan, 1992). Nevertheless, we observed a higher con­
tent of hydroxycholesterols in RMA­CM than in culture 
medium and in NIH­3T3­CM (10­ and 5.5­fold, respectively). 
In particular, the concentrations of hydroxycholesterols, re­
ported as relative abundance of the three molecular ions (m/z 
385, 369, and 367), using 1 mM hydroxycholesterol mix­
ture as a standard (Fig. 1 D), were 0.195 ± 0.012 µmol/ml, 
0.357 ± 0.027 µmol/ml, and 1.973 ± 0.34 µmol/ml for cul­
ture medium, NIH­3T3, and RMA, respectively (Fig. 1 E). 
Two main hydroxycholesterols could be identified on the 
basis of the retention time determined by HPLC analysis using a 
series of standards (Fig. 1 F): 22­HC (22­hydroxycholesterol) 
and 27­HC in a ratio of 4:1 (Fig. 1 G). Accordingly, we found 
that RMA cells expressed transcripts for Cyp11a, Cyp27a1, 
and Ch25h enzymes, which are involved in the synthesis of 
22R­HC, 27­HC, and 25­HC, respectively (Björkhem, 2002; 
Murphy and Johnson, 2008; Mast et al., 2011; Fig. 1 H). In 
similar experiments, we detected 24S­HC in the Lewis lung 
carcinoma (LLC)–CM, and the expression of Cyp46a1 tran­
script by LLC cells (unpublished data). Moreover, we detected 
LXR ligands/oxysterols in tumor­CM from some freshly 
isolated human tumor cells (Fig. 1, I and J). In particular, we 
detected the oxysterols 22­HC and 24S­HC in CM from 
005­mel and MR300 tumor cells (unpublished data). Nota­
bly, we detected in vivo a signature of LXR activation (Abcg1 
and Srebp-1c up­regulation) in cells of the myeloid compart­
ment purified from the bone marrow of RMA­bearing mice, 
but not from mice bearing RMA­SULT2B1b tumors, which 
are unable to produce active LXR ligands/oxysterols (Fig. 1 K). 
These experiments indicate that tumors may release amounts 
of oxysterols sufficient to reach and activate LXR­sensitive 
cells located in organs far away from the tumor.
To evaluate whether these oxysterols were affecting other 
immune cells besides DCs in the tumor microenvironment, 
we analyzed by FACS tumor­infiltrating immune cells from 
14­d established RMA mock­transduced (RMA­Mock) and 
RMA­SULT2B1b and found a higher percentage and num­
ber of CD11bhighGr1high cells infiltrating RMA­Mock tumors 
(Fig. 2, A–C and E). We found a similar difference in terms of 
CD11bhighGr1high cells when comparing mock­transduced 
LLC (LLC­Mock) with LLC­SULT2B1b (Fig. 2, D and F), and 
the LXR ligand­releasing AB1­Mock with AB1­SULT2B1b 
mesotheliomas grown orthotopically in the peritoneal cavity 
(Fig. 2 G and not depicted).
CD11bhighGr1high cells are continuously recruited to tumor sites
To understand whether the accumulation of these cells was 
a result of local proliferation or of their continuous recruit­
ment from circulation, we performed parabiosis experiments, 
joining CD45.1+ and CD45.2+ mice by surgery to establish 
common blood circulation (Wright et al., 2001; Fig. 3 A). 
7 d after RMA challenge in CD45.2+ mice, we separated the 
mice and analyzed tumor infiltrating cell chimerism by FACS 
(Fig. 3 A). As early as 2 d after separation, we observed a nearly 
during MS chemical ionization, as reported at http://www 
.lipidmaps.org. The analysis of hydroxycholesterol extracts from 
control medium or from NIH­3T3 and RMA­CM showed 
the same qualitative fragmentation pattern (Fig. 1, B and C), 
Figure 2. Tumors producing LXR ligands accumulate higher per-
centages of CD11bhighGr1high myeloid cells at the tumor site.  
(A and B) Analysis of CD11bhighGr1high cells infiltrating RMA-Mock and 
RMA-SULT2B1b. (A) Flow cytometry representative of one out of 11–12 
experiments. (B) Immunofluorescence of RMA-Mock tumor stained with 
anti-CD11b (green) and anti-Gr1 (red) mAbs and DAPI (blue). One  
experiment out of four is shown. Bars, 25 µm. (C and D) Percentage of 
CD11bhighGr1high cells infiltrating RMA-Mock (n = 12; mean ± SEM) and 
RMA-SULT2B1b (n = 11; mean ± SEM) tumors (C), and LLC-Mock and 
LLC-SULT2B1b tumors (n = 13; mean ± SEM; D). *, P < 0.05; **, P = 0.001.  
(E and F) Number of CD11bhighGr1high cells/mg of RMA-Mock (n = 12; 
mean ± SEM) or RMA-SULT2B1b (n = 11) tumors (E), and LLC-Mock and 
LLC-SULT2B1b (n = 3; mean ± SEM) tumors (F). *, P < 0.05. (G) Percentage 
of CD11bhighGr1high cells infiltrating AB1-Mock and AB1-SULT2B1b tumors 
(n = 14, Intratumor; n = 8, Ascites; mean ± SEM). *, P < 0.05. Results are 
representative of one (F), two (G), or three (C–E) experiments.
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Migration of CD11bhighGr1high bona fide neutrophils  
toward oxysterols is mediated by G protein–coupled  
receptors (GPCRs) and does not require LXR signaling
To characterize the population of myeloid cells migrating to 
22R­HC, we took advantage of the in vitro migration assay. 
Thus, we compared phenotype and morphology of BM­derived 
migrating (CD11bhighGr1high) and nonmigrating (CD11b+Gr1+) 
cells, collected from the lower and upper chamber of migra­
tion transwells, respectively (Fig. S1 A). Morphological and 
cytochemical analyses of the migrating cells showed the pres­
ence of nuclei similar to immature granulocytes and mature 
neutrophils (Fridlender et al., 2009; unpublished data). FACS 
analysis showed that these cells express Ly6G+ and Ly6b+ 
markers typical of immature/mature neutrophils (Fig. S1 B), 
whereas nonmigrating CD11b+Gr1+ cells were phenotypi­
cally different (Fig. S1 C). Additionally, CD11bhighGr1high cells 
expressed higher levels of CCR1, CXCR4, and CXCR2 
chemokine receptors than CD11b+Gr1+ cells, as expected for 
neutrophils (Fig. S1, B and C). In agreement, neutrophils pu­
rified from bone marrow by standard methods (Corada et al., 
2005) migrated to synthetic and tumor­derived LXR ligands 
in vitro and in vivo (unpublished data).
As the synthetic LXR ligand T1317 was not capable of 
triggering cell migration in vitro (Fig. 4 C), we asked whether 
LXR signaling was, indeed, involved in this migration. 
CD11bhighGr1highLy6G+ cells from Lxr/, /, and / 
mice (Alberti et al., 2001) migrated to 22R­HC as well as wild­
type cells, indicating that LXR signaling is not required for their 
migration (Fig. 5 A). The prototypic receptors involved in leu­
kocyte migration belong to the GPCR superfamily (Rossi and 
Zlotnik, 2000) and can be inhibited by pertussis toxin (PTX). 
PTX inhibited the migration of CD11bhighGr1highLy6G+ cells 
to 22R­HC, thus demonstrating that a GPCR is responsible 
for the migration of these cells toward LXR ligands (Fig. 5 B).
Migration of neutrophils toward 22R-HC in vitro  
and in vivo requires CXCR2 engagement and signaling
The recruitment of CD11bhighGr1highLy6G+ cells (hereafter 
referred to as BM­derived neutrophils) into tumors could be 
complete disappearance of donor CD45.1+CD11bhighGr1high 
cells (Fig. 3, A and B), thus indicating that these cells are 
continuously recruited to the tumor site. These results sug­
gest that LXR ligands may behave as chemoattractants for 
CD11bhighGr1high myeloid cells.
Tumor-derived and naturally occurring LXR ligands  
are chemotactic factors for CD11bhighGr1high cells  
in vitro and in vivo
We speculate that CD11bhighGr1high myeloid cells have a BM 
origin. Hence, we evaluated whether LXR ligands indeed 
attract BM cells by performing in vitro migration assays. 
Total BM cells from naive mice migrated to the LXR ligand 
22R­HC but not to the inactive isomer 22S­HC (Fig. 4 A). 
To identify the migrating subset of BM cells, we purified and 
tested the CD11b+ and CD11b populations. Migratory cells 
were in the CD11b+ cell fraction (Fig. 4 B and not depicted). 
We observed by FACS analysis that nonmigrating cells co­
expressed CD11b and Gr1 markers at intermediate levels 
(CD11b+Gr1+ cells), whereas migrating cells were CD11b­
highGr1high (Fig. S1 A), resembling the cell population detected 
in vivo within the tumors (Fig. 2 A). Among the other oxy­
sterols tested, 24S­HC, 27­HC, 19­HC, and 25­HC also in­
duced cell migration (Fig. 4 C). On the contrary, cholesterol, 
some sterol­derived nuclear receptor ligands, and the syn­
thetic LXR ligand T0901317 (T1317) were unable to induce 
cell migration (Fig. 4, C and D).
To prove that tumor­derived LXR ligands were involved 
in the migration of CD11bhighGr1high cells in vivo, we in­
jected total BM cells previously labeled with the fluorescent 
dye CFSE (CFSE+CD45.2+) in NOD­SCID mice bearing 
RMA­Mock or RMA­SULT2B1b. 18 h later, we analyzed tu­
mors for the presence of injected cells (CFSE+) and found a 
higher percentage and number of exogenous (CFSE+CD45.2+) 
CD11bhighGr1high cells infiltrating RMA­Mock, as com­
pared with RMA­SULT2B1b tumors (Fig. 4, F and G, bot­
tom). As expected, the endogenous (CD45.1+) CD11bhigh 
Gr1high cells were also more abundant in RMA­Mock (Fig. 4, E 
and G, top).
Figure 3. Recruitment of CD11bhighGr1high myeloid cells within LXR ligand-releasing tumors. (A and B) Parabiosis experiments. CD11bhighGr1high 
gated cells were analyzed for CD45.1 marker at day 0, 2, 4, and 7 after mice separation. A representative FACS analysis of three experiments is shown (A). 
(B) Quantification of the FACS analysis as in A performed on three mice per group (n = 3 mice per group; mean ± SEM).
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neutrophils with 22R­HC induced the heterologous desensiti­
zation of the cells to the subsequent response to CXCL5 but 
did not affect the migration to CXCL12 (Fig. 5 C). These 
results suggest that 22R­HC and CXCL5 may share the same 
chemotactic receptor, namely CXCR2. Accordingly, heterolo­
gous desensitization of BM­derived neutrophils with CXCL5 
mediated by the CXCL12–CXCR4 and CXCL5–CXCR2 
axes (Yang et al., 2008). We therefore performed a migration 
assay toward 22R­HC, CXCL5, CXCL12, and CCL3, a ligand 
of CCR1. BM­derived neutrophils migrated to 22R­HC, 
CXCL5, and SDF­1, whereas migration to MIP­1 was neg­
ligible (Fig. 5 C). In addition, the pretreatment of BM­derived 
Figure 4. In vitro and in vivo migration of BM-derived CD11bhighGr1high myeloid cells toward natural and tumor-released LXR ligands.  
(A and B) In vitro migration of total BM cells (A) and CD11b+ purified cells (B) toward 15 µM of the LXR ligands 22R-HC and 22S-HC (mean ± SEM).  
Results are representative of four experiments. **, P < 0.01; ***, P < 0.0001. (C and D) Migration of purified CD11b+Gr1+ cells to LXR ligands and to other 
sterol-derived compounds. (C) 22R-HC, 24S-HC, 27-HC, 19-HC, 25-HC, 7-HC, 4-HC, 7-OH, 24,25 EpoxyChol, T1317, and 22S-HC ligands were tested 
at 15 µM. Because of toxicity, 7-HC and 24,25-EC were tested at 5 µM, whereas 19-HC was tested at 1 µM (mean ± SEM). Results are representative of 
two experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.0001. (D) CDCA, chenodeoxycholic acid; GlycoCDCA, glycine chenodeoxycholic acid. CDCA and gly-
coCDCA are FXR ligands, and pregnenolone is an SXR ligand (mean ± SEM). Results are representative of three experiments. ***, P < 0.0001. (E and F) FACS 
analysis of endogenous CD45.1+CD11bhighGr1high (E) and exogenous CFSE+CD11bhighGr1high (F) cells infiltrating RMA-Mock and RMA-SULT2B1b tumors 
after i.v. infusion of CFSE+ BM cells. One of out of five experiments is shown. Numbers in the plots represent mean ± SEM of the percentages of endog-
enous and exogenous cells (n = 5). (G) Number of endogenous CD45.1+CD11bhighGr1high and exogenous CFSE+CD11bhighGr1high cells infiltrating RMA-Mock 
and RMA-SULT2B1b tumors (n = 5; mean ± SEM). Results are representative of five mice per group. ***, P = 0.0003.
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involved in the migration of BM­derived neutrophils toward 
22R­HC (Fig. 5 F).
To investigate the role of the oxysterol–CXCR2 axis in 
neutrophil recruitment in vivo, we performed matrigel plug 
experiments. To distinguish neutrophil migration induced by 
22R­HC from that induced by other CXCR2­binding che­
mokines that are locally released during the inflammation in­
duced by matrigel inoculation, we injected mice with matrigel 
or their treatment with the CXCR2 antagonist SB225002 
(White et al., 1998) inhibited their migration to CXCL5 
and to 22R­HC (Fig. 5, D and E). To finally prove the role 
of the CXCR2 receptor, we performed migration ex­
periments using BM­derived neutrophils from Cxcr2/ 
mice (Cacalano et al., 1994). These cells did not migrate 
to either CXCL5 or 22R­HC, whereas they migrated to 
SDF­1, demonstrating that CXCR2 is indeed the receptor 
Figure 5. Migration of CD11bhighGr1high neutrophils toward LXR ligands is independent of LXR and mediated by the GPCR CXCR2. (A) In vitro 
migration of CD11b+Gr1+ cells from wild-type (WT) and Lxrs-deficient mice to 15 µM 22R-HC or 22S-HC (mean ± SEM). Results are representative of two 
experiments. *, P < 0.05; **, P < 0.01. (B) Migration of PTX-treated CD11b+Gr1+ cells to 15 µM 22R-HC or 22HS-HC (mean ± SEM). Results are representa-
tive of two experiments. **, P < 0.01. (C) Migration of pretreated CD11b+Gr1+ cells to 15 µM 22R-HC, or 100 ng CXCL5, CXCL12, or CCL3 (mean ± SEM). 
Results are representative of four experiments. **, P < 0.01; ***, P < 0.0005. (D and E) Migration of CXCL5 (E) or SB225002 (F) pretreated CD11b+Gr1+ cells 
to 15 µM 22R-HC or 100 ng CXCL5 (mean ± SEM). Results are representative of two experiments. *, P < 0.05; **, P < 0.01. (F) Migration of WT, Cxcr2+/, 
and Cxcr2/ CD11b+Gr1+ cells to 15 µM 22R-HC, or 100 ng CXCL5 or CXCL12 (mean ± SEM). Results are representative of four experiments. **, P < 0.01; 
***, P < 0.0001.
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Oxysterol-migrating neutrophils favor tumor growth  
by promoting neoangiogenesis or immunosuppression
Because the inactivation of oxysterols by SULT2B1b­ex­
pressing tumors induces tumor growth delay or rejection 
(Villablanca et al., 2010), we hypothesized that neutrophils 
recruited by tumor­derived oxysterols could exert protu­
mor activities (i.e., immunosuppression and/or neoangio­
genesis), as already reported by others (Yang et al., 2004; 
Nozawa et al., 2006; Fridlender et al., 2009). Therefore, we 
investigated the protumor functions of 22R­HC–migrating 
plugs containing CXCL5, 22R­HC, or 22S­HC alone or in the 
presence of anti­CXCL1, 3, 5, and 7 mAbs (Fig. 6 A). 5 h later, 
plugs were analyzed for the presence of CD11b+Ly6G+ neu­
trophils (Fig. 6 A). CXCL5 and 22R­HC induced a high 
recruitment of neutrophils, whereas 22S­HC behaved as matri­
gel alone (Fig. 6 A). Anti­CXCL mAbs almost completely in­
hibited migration induced by CXCL5 (88.6% inhibition) and 
22S­HC (80% inhibition), whereas 22R­HC–induced migra­
tion was only partly inhibited (48.3% inhibition) (Fig. 6 A), 
indicating that 22R­HC is indeed able to recruit neutrophils 
in vivo. Accordingly, the percentage of neutrophil infiltration 
in RMA­Mock and RMA­SULT2B1b (Fig. 2 C) correlated 
with the availability of active oxysterols, but not with the con­
tent of CXCL1 and CXCL5 chemokines detected within the 
tumor, as shown by quantitative analyses reporting higher lev­
els of CXCL1 and CXCL5 chemokines in RMA­SULT2B1b 
than in RMA­Mock (Fig. 6, B and C). 22R­HC–induced 
migration was mediated by CXCR2, as it was inhibited when 
mice bearing 22R­HC–embedded plugs were treated with 
the CXCR2 antagonist SB225002 (Fig. 6 D). Finally, in vivo 
neutrophil migration was also independent of LXR signaling, 
as demonstrated by the migration of Lxr/ neutrophils 
toward 22R­HC–embedded matrigel plugs (Fig. 6 E).
The engagement and activation of CXCR2 by 22R­HC 
was demonstrated by three experimental approaches. First, 
22R­HC was able to induce CXCR2 down­regulation, as 
evaluated by FACS analysis (Fig. 7 A). Second, in a concentra­
tion­dependent manner, 22R­HC stimulated the binding of 
35S­GTPS to membranes from CXCR2­expressing L1.2 
cells, but not from Mock­L1.2 cells, with an EC50 value of 
1.32 ± 0.25 µM (Fig. 7, B and C). On the contrary, 22S­HC 
did not activate any 35S­GTPS binding, suggesting that this 
oxysterol does not interact with CXCR2 (Fig. 7, B and C). 
As expected, the natural CXCR2 ligand IL­8 stimulated 
35S­GTPS binding, with an EC50 of 2.50 ± 0.17 nM (Fig. 7 B). 
Furthermore, we observed a dose­dependent inhibition of 
35S­GTPS binding when 22R­HC was displaced by increas­
ing concentrations of the CXCR2 antagonist SB225002 
(Fig. 7 D). Third, 22R­HC inhibited the cAMP formation 
elicited by 1 µM forskolin in a dose­dependent manner, with 
an EC50 value of 1.32 ± 0.25 µM in CXCR2­expressing 
CHOK1 but not in Mock­CHOK1 cells (Fig. 7, D and E). 
Yet in this system, the CXCR2 antagonist SB225002 coun­
teracted the inhibition of cAMP formation elicited by 10 µM 
22R­HC in a dose­dependent manner (unpublished data). 
Notably, the EC50 values of 22R­HC–CXCR2 interactions 
that we detected (1.32 µM) are in the same range as those re­
ported for 22R­HC–LXR activation (1.5 µM; Janowski et al., 
1996), indicating that 22R­HC oxysterol is able to activate 
both LXRs and CXCR2 with a similar potency.
Additionally, 22R­HC and 25­HC displaced 125I­IL­8 
from CXCR2­expressing cells in a dose­dependent manner 
(Fig. 7 G), whereas 22S­HC and 4­HC (two oxysterols un­
able to promote cell migration, Fig. 4 C) did not (unpublished 
data), thus suggesting that 22R­HC, 25­HC and IL­8 could 
bind the same domain of CXCR2.
Figure 6. In vivo migration of neutrophils toward 22R-HC Oxy-
sterol. (A) Total number of CD11bhighLy6G+ neutrophils migrated toward 
matrigel plugs embedded with 500 ng CXCL5, or 500 µM 22R-HC or 22S-HC 
in the absence (black bars) or presence (white bars) of mAbs blocking 
CXCL1, 3, 5, and 7 chemokines. Neutrophil migration toward matrigel 
alone is represented in red. Results are representative of three to six mice 
per group (mean ± SEM). **, P < 0.01; ***, P < 0.0001. (B and C) Quantifi-
cation of tumor environment–produced CXCL1 and CXCL5 chemokines. 
Cell suspensions from 7-d established RMA-SULT2B1b tumors release 
higher amounts of CXCL5 (B) and CXCL1 (C) chemokines than cell suspen-
sions from 7-d established RMA-Mock (mean ± SEM). Data are represen-
tative of three experiments. *, P < 0.05; **, P < 0.01. (D) Total number of 
CD11bhighLy6G+ neutrophils migrated toward matrigel plugs embedded 
with 500 µM of 22R-HC after the treatment of mice with the CXCR2  
antagonist SB225002 (white bars) or vehicle (black bars; n = 6 mice; mean 
± SEM). Results are representative of two experiments. *, P < 0.05.  
(E) Total number of Lxr/ CD11bhighLy6G+ neutrophils infiltrating 
matrigel plugs embedded with 500 µM 22R-HC or 22S-HC. Results are 
representative of three mice per group (mean ± SEM). **, P = 0.0015.
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Figure 7. The Oxysterol 22R-HC binds and activates CXCR2. (A) Flow cytometric analysis of CXCR2 expression by CD11bhighGr1high cells untreated 
(UT) or incubated with CXCL12, CXCL5, 22R-HC, 22S-HC, or SB225002 (mean ± SEM). Results are representative of three experiments. **, P < 0.01;  
***, P < 0.0005. (B and C) Dose-dependent stimulation of 35S-GTPS binding on L1.2-CXCR2 (B) or L1.2-mock (C) cellular membranes by oxysterols and  
IL-8. All data are expressed as percentage of basal 35S-GTPS binding (set to 100%; mean ± SEM). Results are representative of three experiments. *, P < 0.05;  
**, P < 0.01 versus basal value. (D) SB225002 inhibits 35S-GTPS binding stimulated by 10 µM 22R-HC (IC50 of 22.41 ± 4.83 nM) and by 10 nM IL-8 used 
as control (IC50 of 16.64 ± 3.64 nM). All data are expressed as percentage of basal 35S-GTPS binding (set to 100%; mean ± SEM). Results are representa-
tive of three experiments. **, P < 0.01; ***, P < 0.001 versus basal value. (E and F) Dose-dependent inhibition of forskolin-induced cAMP accumulation in 
CXCR2-expressing cells (E) or mock cells (F) by oxysterols and IL-8. Results are expressed as percentage of FK-stimulated cAMP levels, set to 100%  
(mean ± SEM). Results are representative of three experiments. **, P < 0.01; ***, P < 0.001 versus basal value. (G) Percentage of 125I-IL-8 bound to  
L1.2-CXCR2 cells in the presence of 100, 50, 10, or 1 µM 22R-HC or 22S-HC (mean ± SEM). Results are representative of three experiments.
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neutrophils in vitro and in vivo in RMA, AB1, and LLC 
tumor models.
In vitro, BM­derived 22R­HC–migrating neutrophils 
(CD11bhighGr1high) were unable to suppress both the priming 
(Fig. 8 A) and the restimulation (Fig. 8 B) of OVA­specific 
OT­I T cells. However, they released a high amount of total 
MMP­9 (Nozawa et al., 2006; Fig. 8 C), expressed high mRNA 
levels of the proangiogenic factor Bv8 (Shojaei et al., 2008; 
Fig. 8 D), and released Bv8 when exposed for 18 h to tumor 
CM (Fig. 8 E).
In vivo, we tested whether RMA­infiltrating neutrophils 
were endowed with immunosuppressive functions, as neu­
trophils may acquire an immunosuppressive ability within 
the tumor microenvironment (Fridlender et al., 2009; De 
Santo et al., 2010). However, we failed to detect any sup­
pression of OT­I T cell activation (Fig. 8 F). In agreement 
with the reported in vitro proangiogenic functions, we ob­
served an increased number of abnormal CD31+ vessels 
by immunohistochemistry (Fig. 8 G) and a higher percent­
age of CD45CD31+ cells in 6­d established matrigel plugs 
Figure 8. Oxysterol-migrating neutrophils enhance RMA tumor growth by promoting neoangiogenesis. (A and B) Proliferation of OT-I  
splenocytes naive (A) or memory (B) labeled with the cytosolic dye CFSE and pulsed with the ovalbumin peptide SIINFEKL in the presence of 50%  
CD11bhighGr1high (22R-HC migrating) or CD11b+Gr1+ (22R-HC nonmigrating) cells (mean ± SEM). Results are representative of two experiments.  
(C) 22R-HC migrating neutrophils release higher amounts of MMP9 than nonmigrating cells and splenocytes (mean ± SEM). Results are representative of 
two experiments. ****, P < 0.0001. (D) qRT-PCR analysis for Bv8 mRNA expression in CD11b+, and 22R-HC migrating (CD11bhighGr1high) and nonmigrating 
(CD11b+Gr1+) cells (mean ± SEM). Results are representative of three experiments. **, P < 0.01. (E) Release of Bv8 protein by CD11b+, and 22R-HC migrat-
ing (CD11bhighGr1high) and nonmigrating (CD11b+Gr1+) cells and by 22R-HC migrating cells incubated with medium or RMA-CM. RMA-CM alone was also 
tested (mean ± SEM). Results are representative of three experiments. ***, P < 0.0001. (F) Proliferation of OT-I naive splenocytes labeled with the cytosolic 
dye CFSE and pulsed with the SIINFEKL peptide in the presence of 50% (1:2) or 25% (1:4) of CD11bhighLy6G+ neutrophils isolated from RMA tumors  
(mean ± SEM). Results are representative of two experiments. (G) Immunohistochemistry showing CD31+ endothelial cells in RMA alone (left) or coin-
jected with CD11bhighGr1high neutrophils (right). Arrows indicate enlarged and abnormally shaped vessels. One experiment out of four is shown. Bars,  
100 µm. (H) Percentage of CD45CD31+ cells (presented as in A). Individual mouse data are shown (mean, horizontal line). *, P < 0.05; **, P < 0.01.  
(I) Box plots representing weights of RMA tumors alone (n = 13) or coinjected with 22R-HC migrating (CD11bhighGr1high; n = 16) or nonmigrating 
(CD11b+Gr1+; n = 19) cells. Results are representative of three experiments. *, P < 0.05; **, P < 0.01.
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containing RMA (Fig. 8 H) or B16F1 (not depicted) ad­
mixed with 22R­HC–migrating CD11bhighGr1high neutro­
phils. These results paralleled the increased tumor weight we 
observed when RMA tumors were admixed with 22R­HC–
migrating CD11bhighGr1high neutrophils (Fig. 8 I). In contrast, 
we observed tumor growth delay, decrease of neutrophil 
but not of CD11b+Gr1+ cell infiltration, and reduction of 
CD45CD31+ endothelial cells when we treated RMA­
bearing mice intratumor with an anti­Gr1 mAb (Fig. 9, A–C; 
and not depicted).
Figure 9. Neutrophil depletion and CXCR2 inactivation control tumor growth by reducing angiogenesis in RMA tumor model. (A) RMA tumor 
growth in mice administered with 30 µg anti-Gr1 or control antibody (n = 15 mice per group). Results are representative of two experiments. ***, P = 
0.0001. (B) Percentage and number of RMA-infiltrating neutrophils after intratumor administration of anti-Gr1 or control antibody (n = 5 mice per 
group; mean ± SEM). *, P = 0.038; **, P = 0.0033. (C) Percentage of CD45CD31+ cells in RMA injected with anti-Gr1 or control antibody (n = 7 mice per 
group). Individual mouse data are shown (mean, horizontal line). Results are representative of two experiments. **, P = 0.0031. (D) Treatment of RMA-
Mock–bearing mice with vehicle or 0.8 mM SB225002 (n = 7–8; mean ± SEM). Results are representative of one out of two experiments. **, P < 0.001;  
***, P = 0.0009. (E) Growth of RMA in WT and Cxcr2/ chimera mice treated or not with 0.8 mM SB225002 (n = 5–6; mean ± SEM). Results are represen-
tative of one out of two experiments. *, P < 0.05; **, P = 0.0001. (F) Percentage of CD11b+Ly6G+ neutrophils infiltrating RMA-Mock injected in WT (n = 5; 
mean ± SEM) or in Cxcr2/ (n = 6; mean ± SEM) chimera mice. **, P = 0.0010. (G) Percentage of CD45CD31+ cells in RMA-Mock injected in WT or 
Cxcr2/ chimera mice (n = 5 mice per group). Individual mouse data are shown (mean, horizontal line). *, P = 0.01.
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To investigate the role of CXCR2 receptor activation 
in vivo and to mimic a possible pharmacologic antitumor 
therapy, we treated RMA­bearing mice with the CXCR2 
antagonist SB225002 and found a significant delay of RMA 
growth (Fig. 9 D). However, as in the tumor microenviron­
ment, CXCR2 is expressed by neutrophils and at lower levels 
(unpublished data) by some mature endothelial cells (Strieter 
et al., 2006), and we performed tumor growth experiments in 
wild­type and in Cxcr2/ bone marrow chimera to distinguish 
the role of the two cell populations. SB225002 significantly 
delayed tumor growth in wild­type but not in Cxcr2/ chi­
mera mice (Fig. 9 E). Moreover, in these tumors we detected 
a reduced percentage of neutrophils and CD45CD31+ en­
dothelial cells (Fig. 9, F and G), thus demonstrating that in the 
RMA tumor model, tumor­released oxysterols favor tumor 
growth by recruiting proangiogenic neutrophils. Whether 
oxysterols may also have an effect on BM­derived endothelial 
progenitor cells expressing CXCR2 deserves a deeper inves­
tigation in suitable tumor models (Shaked et al., 2008).
As reported above, we also investigated the possible protu­
mor role of oxysterol­recruited neutrophils in AB1 and LLC 
tumor models. We observed a reduced number of perito­
neal tumor nodules associated with a reduction of neutro­
phils and CD45CD31+ endothelial cells when we treated 
AB1­bearing mice with the CXCR2 antagonist SB225002 
(Fig. 10, A–C). Similar results were obtained by inactivating 
oxysterols with SULT2B1b. Indeed, we observed a lower 
number of peritoneal tumor nodules and prolonged survival 
of mice bearing AB1­SULT2B1b as compared with mice 
bearing AB1­Mock tumors (not depicted and Fig. 10 D). The 
prolonged survival was associated with a lower percentage of 
infiltrating neutrophils (Fig. 2 G) and CD45CD31+ endo­
thelial cells (Fig. 10 E).
In the LLC tumor model, we also observed a significant 
growth delay when we treated tumor­bearing mice with 
SB225002 (Fig. 10 F) and when LLC was grown in Cxcr2/ 
bone marrow chimera mice (Fig. 10 G). In this experimental 
setting, tumor growth delay paralleled the reduction of neu­
trophil infiltration (Fig. 10 H). However, we failed to detect 
any difference in the percentage of CD45CD31+ cells be­
tween LLC tumors from wild­type and Cxcr2/ chimera 
mice (Fig. 10 I). Similar results were obtained when BM­ 
derived neutrophils were coinjected in matrigel admixed 
with LLC tumor cells (Fig. 10 J). These results suggest that 
mechanisms different from those acting in the RMA and AB1 
tumors are responsible for tumor promotion by neutrophils 
in LLC tumor, such as immune suppression. Indeed, neutro­
phils purified from LLC tumors were able to suppress OT­I 
T cell activation (Fig. 10 K), thus indicating that in this 
tumor model, neutrophils mainly exert their protumori­
genic activity by the immune suppression of antitumor im­
mune responses.
Altogether, these results indicate that some tumor­derived 
oxysterols recruit neutrophils in a CXCR2­dependent man­
ner, which in turn exploit (i.e., neoangiogenesis) or acquire 
(i.e., immune suppression) protumor activities, thus favoring 
tumorigenesis. The inactivation of the oxysterol–CXCR2–
neutrophil axis is able to effectively counteract tumor growth.
DISCUSSION
In recent years, bone marrow–derived immature and mature 
myeloid cells have been extensively investigated, as they are 
endowed with a high capability to exert protumor functions 
(Gabrilovich et al., 2012). Indeed, these cells can suppress 
antigen­specific immune responses (immature myeloid cells 
or myeloid­derived suppressor cells), exert a proangiogenic 
activity (immature myeloid cells or neutrophils; Murdoch 
et al., 2008; Motz and Coukos, 2011), or induce chemoresis­
tance and invasion or metastasis (immature myeloid cells; Yang 
et al., 2008; Acharyya et al., 2012). These cells are recruited to 
tumor microenvironment mainly by chemokines constitu­
tively released by tumor and stromal cells (Mantovani et al., 
2010; Qian et al., 2011; Acharyya et al., 2012) or produced 
after some aggressive treatments (Kerbel, 2008). Our study 
highlights an unanticipated role of tumor­derived oxysterols/
LXR ligands, which contribute to the recruitment of protu­
mor neutrophils in a CXCR2­dependent manner, ultimately 
favoring tumor growth.
The migration of neutrophils to the oxysterol 22R­HC 
did not require LXR signaling because it occurred also with 
neutrophils from Lxr/, /, and / mice but re­
quired the functional interaction with the GPCR CXCR2, 
as demonstrated by the 22R­HC–mediated activation of 
35S­GTPS binding and by the inhibition of cAMP forma­
tion elicited by forskolin stimulation. The interaction between 
oxysterols and GPCRs has recently been described to occur 
for the oxysterol 7,25­HC, which specifically binds EBI2 
but not LXRs (Hannedouche et al., 2011). The CXCR2­ 
activating oxysterols identified by our study have been pri­
marily reported to bind LXRs (Janowski et al., 1996). 
However, the EC50 values of CXCR2/22R–HC interaction 
we measured (1.32 µM) turned out to be very similar to those 
reported by Janowski et al. (1996) for LXR/22R–HC inter­
action (1.5 µM). In this context, our results are in agreement 
with a recent in vitro study showing that the oxysterol 20S­HC 
activates the 7­transmembrane oncoprotein smoothened, in 
addition to LXRs, with a similar potency (i.e., 3 µM for 
smoothened, and 4–7 µM for LXR; Nachtergaele et al., 
2012). Notably, Nachtergaele et al. (2012) reported that the 
oxysterol 20S­HC could act as allosteric modulator of protein 
binding. Instead, in our system we did not observe any syner­
gistic effect when neutrophils were allowed to migrate in vitro 
toward mixtures of 22R­HC and CXCR2 ligands (unpub­
lished data). Altogether, these observations identify the oxy­
sterols as molecules endowed with a broad range of activity 
(i.e., binding to LXRs and/or to other receptors) depend­
ing on the tissue and the pathophysiologic conditions of 
the microenvironment in which they are produced. Indeed, 
in our tumor models, the dual role of oxysterols, i.e., the 
CXCR2­mediated recruitment of protumorigenic neutro­
phils and the recently described LXR­dependent dampening of 
DC migration (Villablanca et al., 2010), coexists and adds up 
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Figure 10. Pharmacologic or genetic CXCR2 inactivation controls tumor growth by reducing angiogenesis and immunosuppression in AB1 and 
LLC tumor models. (A) Number of peritoneal tumor nodules in AB1-bearing mice treated with vehicle or 0.8 mM SB225002 (n = 5 mice per group). Individual 
mouse data are shown (mean, horizontal line). **, P = 0.0071. (B) Percentage of CD11bhigh Gr1highLy6G+ neutrophils infiltrating AB1 tumors from mice treated with 
vehicle or with SB225002 (n = 5 mice per group; mean ± SEM). **, P = 0.0045. (C) Percentage of CD45CD31+ cells in AB1 tumors from mice treated with vehicle 
or SB225002 (n = 5 mice per group). Individual mouse data are shown (mean, horizontal line). *, P = 0.011. (D) Survival of mice injected with AB1 tumor cells 
expressing SULT2B1b or mock-transduced. Mean ± SEM of one experiment. Statistical comparison was performed by the log-rank test with 10 mice per group.  
P < 0.0001. (E) Percentage of CD45CD31+ cells in AB1-Mock and AB1-SULT2B1b tumors (n = 13). Individual mouse data are shown (mean, horizontal line). 
Results are representative of two experiments. ***, P < 0.0001. (F) Growth of LLC tumor in mice treated or not with 0.8 mM SB225002 (seven mice per group; 
mean ± SEM). *, P < 0.05; ***, P < 0.001. (G) Growth of LLC in WT and Cxcr2/ chimera mice. (n = 12–13 mice per group; mean ± SEM). Results are representative 
of two experiments. ***, P < 0.0001. (H) Percentage of CD11b+Ly6G+ neutrophils infiltrating LLC injected in WT or in Cxcr2/ chimera mice (n = 4 mice per group; 
mean ± SEM). Results are representative of one out of two experiments. ***, P < 0.0001. (I) Percentage of CD45CD31+ cells in LLC injected in WT or Cxcr2/ 
chimera mice (n = 4 mice per group). Individual mouse data are shown (mean, horizontal line). (J) Percentage of CD45-CD31+ cells in LLC tumors alone (n = 8) or 
coinjected with 22R-HC–migrating neutrophils (n = 9). Individual mouse data are shown (mean, horizontal line). Results are representative of one out of two ex-
periments. ns, not significant. (K) Proliferation of OT-I naive splenocytes labeled with the cytosolic dye CFSE and pulsed with the SIINFEKL peptide in the presence 
of 50% (1:2), 25% (1:4), or 12.5% (1:8) of neutrophils isolated from LLC tumors (mean ± SEM) Results are representative of two experiments. ***, P < 0.0001.
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to promote tumor growth. This is confirmed by tumor growth 
experiments in Lxr/ bone marrow chimera mice, in which 
the growth rate of the oxysterol­releasing RMA­Mock is, how­
ever, higher than that of RMA­SULT2B1b, where the oxyste­
rols are inactivated (unpublished data). Notably, in our tumor 
model LXR­ does not seem to play a major role, as RMA­
Mock showed the same growth rate in Lxr/ and wild­
type bone marrow chimera mice (unpublished data). The 
identification of oxysterols (22R­HC, 20S­HC, etc.) endowed 
with the promiscuous ability to activate two different recep­
tors highlights the need to carefully investigate these mole­
cules to identify new biological functions associated with 
oxysterols in different physiological and pathological condi­
tions, including tumors.
The in vivo experiments using 22R­HC–embedded 
matrigel plugs indicate that oxysterols may contribute, to­
gether with CXCL chemokines (Fig. 6 A), to neutrophil re­
cruitment within tumor microenvironment, as indicated by 
the detection of higher numbers of neutrophils in oxysterol­
releasing tumors. These results are further corroborated by the 
observation that the percentage of neutrophil infiltration cor­
related with the availability of active oxysterols, but not with 
the content of CXCL1 and CXCL5 chemokines detected 
within the tumor (Fig. 6, B and C). Recently, different mo­
lecular mechanisms able to modify protein structure within 
tumors (Nagaraj et al., 2007; Molon et al., 2011) or in dam­
aged tissues (Venereau et al., 2012) have been reported. Par­
ticularly, protein nitration has been demonstrated to modify 
the chemotactic capacity of chemokines present in tumors. In 
this context, the chemoattractant ability of oxysterols might 
play a relevant role in the tumor microenvironment, in which 
chemokines could be structurally and functionally altered 
(Molon et al., 2011). Whether, this mechanism is also relevant 
for the recruitment of immune cells in some phases of physi­
ological inflammatory processes (i.e., wound healing) will re­
quire further studies.
We report that RMA tumor cells produce 22R­HC and 
27­HC oxysterols and other species that we are characteriz­
ing (Fig. 1 G), whereas LLC tumor cells produce 24S­HC 
(not depicted). However, a clear picture of how and when 
oxysterols are produced within tumor microenvironment re­
mains elusive. RMA and LLC constitutively express transcripts 
for the oxysterol­generating enzymes Cyp11a1, Cyp27a1, and 
Cyp46a1 (Fig. 1 H and unpublished data; Björkhem, 2002; 
Mast et al., 2011). However, a nonenzymatic pathway, involv­
ing reactive oxygen species that are frequently increased in 
the tumor microenvironment (Murphy and Johnson, 2008), 
can also participate in oxysterol generation, further contribut­
ing to the production and accumulation of oxysterols in vivo. 
Moreover, recent studies reveal additional complexity. In­
deed, other cells of the microenvironment have been reported 
to express oxysterol­producing enzymes and to generate 
oxysterols (Diczfalusy et al., 2009; Yi et al., 2012). Because 
tumor microenvironment is a complex tissue, in which all 
the cells described so far to generate oxysterols are present 
(tumor cells, stromal cells, and immune cells), we speculate that 
appropriate mouse models are needed to investigate the rela­
tive contribution of oxysterol­producing cells within tumors. 
The investigation of cells and factors regulating oxysterol pro­
duction should clarify in the near future the mechanisms re­
sponsible for oxysterol generation, their overall contribution 
to tumorigenesis, and possibly identify drugs capable of in­
hibiting their in vivo generation.
The demonstration that some freshly isolated human 
tumor cells release oxysterols able to bind both LXR and 
CXCR2 (Fig. 1 I and J; and not depicted), along with the 
observation that higher numbers of intratumor neutrophils 
severely affect overall survival of kidney cancer patients 
(Jensen et al., 2009), suggests that manipulating LXR ligands 
and their interaction with CXCR2 and immune cells could 
provide additional targets for the development of new anti­
tumor therapies.
MATERIALS AND METHODS
Animal studies and reagents. C57BL/6 CD45.1 or CD45.2, Balb/C and 
NOD­SCID mice were from Charles River and Harlan. Cxcr2+/ and 
Cxcr2/ mice were from The Jackson Laboratory. Lxr/ knockout mice 
were generated as described previously (Alberti et al., 2001). Mice were 
maintained in the pathogen­free facility of San Raffaele Scientific Institute. 
Experiments were conducted in compliance with the Institutional Animal 
Care and Use Committee program (IACUC no. 341 and 436). Most anti­
bodies were from BD. CXCL5, CXCL12, CCL3, and IL­8 were from R&D 
Systems. 22R­HC, 22S­HC, 25­HC, 24,25 Epoxycholesterol, 7­HC, Cho­
lesterol, chenodeoxycolic acid, and Glyco­CDCA were from Sigma­Aldrich 
and from Avanti Polar Lipids. 24­HC, 27­HC, 4­HC, and 7­HC were 
from Avanti Polar Lipids. 19­HC was from Santa Cruz Biotechnology, Inc. 
T0901317 and Pregnenolone were from Cayman. CFSE was used at 4 µM 
(Molecular Probes). PTX and PTX B­Oligomer were from Enzo Life Sci­
ences. Rat anti–mouse CD11b MicroBeads were from Miltenyi Biotec. 
SB225002 was from Tocris. Dead Cell Stain kit (Live/Dead Fixable Far red) 
was from Invitrogen. Buthlyhydroxytoluene (BHT) and solvents of HPLC 
grade were obtained from Sigma­Aldrich. The C18 cartridges (360 mg) were 
obtained from Waters Chromatography EUROPE (Netherlands).
Promoter reporter assay for nuclear receptor activity. We transfected 
105 HEK293 cells/well with 100 ng of the plasmid pMH100X4­TK­ 
luc/well together with 100 ng/well pCMX­Gal4­LXR plasmid using 
FuGene 6 Transfection Reagent (Roche). 4 h after transfection, we treated the 
cells with tumor CM for 24 h. Luciferase activity was evaluated by Luciferase 
Reporter Assay Systems (Promega) according to the manufacturer’s pro­
tocol. We used 30 ng ­galactosidase/well for transfection normalization 
(Villablanca et al., 2010).
Sample collection and solid-phase extraction of hydroxycholester-
ols. All the cell lines analyzed were seeded at 105 cells/ml and cultured for 
48 h. Then, conditioned media were collected, added to butylhydroxytolu­
ene (40 µM final concentration) to avoid cholesterol oxidation (Gilardi et al., 
2009), and stored at 80°C until processing. Hydroxycholesterol extraction 
was made as previously described (Burkard et al., 2004). In brief, the C18 
cartridges were preconditioned with 1 ml n­heptane/2­propanol (50:50, 
vol/vol), 1 ml methanol, and 2 ml of water. 2 ml of the cell­free medium was 
then applied to the cartridge using only gravity. Afterward, the cartridge was 
washed with 4 ml methanol­water (75:25, vol/vol) and briefly dried under 
vacuum. Hydroxysterols were desorbed with 2 ml n­heptane/2­propanol 
(50:50, vol/vol) using only gravity. The eluted substances were dried at 30°C 
by evaporation (Rotavapor), and the residue was dissolved in 200 µl of meth­
anol and subjected to CI­MS analysis and HPLC analysis.
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MS analysis. MS was performed on a Thermo Electron TRACE DSQTM 
spectrometer through the rapid heating filament Direct­Exposure Probe 
(DEP) insertion mode. The MS analyses were performed in chemical ioniza­
tion (CI­MS) using methane as reactant gas at an electron energy of 70 eV 
with a source temperature of 200°C.
High performance liquid chromatography (HPLC). An HPLC 
method was developed based on the HPLC­ESI­MS methods described in 
McDonald et al. (2007). Hydroxycholesterols were resolved using reverse 
phase HPLC (RP­HPLC) equipped with a Waters 996 Photodiode Array 
Detector (wavelength 213 nm). A 100 µl aliquot of lipid extract (in methanol) 
or standard solution was loaded onto a RP­HPLC column (5 µm, 250 × 4 mm 
LiChrospher 100 RP18 column; Merck) equipped with a guard column. 
Elution of hydroxycholesterols was performed at flow rate of 300 µl/min, 
with a gradient formed by the solvent system A, consisting of methanol/
water (85:15, vol/vol) and solvent system B consisting of methanol, both 
containing 5mM ammonium acetate. The gradient elution program was as 
follows: for RMA­CM analysis, 3 min with solvent A, 33 min with a linear 
gradient from 100% solvent A to 100% solvent B, 15 min with 100% solvent 
B, 5 min with a linear gradient from 100% solvent B to 100% solvent A; for 
all the other CM analyzed, 3 min with solvent A, 55 min with a linear gradi­
ent from 100% solvent A to 100% solvent B, 10 min with 100% solvent B, 
5 min with a linear gradient from 100% solvent B to 100% solvent A, and 
maintained for 10 min to reequilibrate the column before the next run.
Chemotaxis assay. Chemotaxis assays were performed using 5­µm pore 
polycarbonate filters in a 24­well transwell chamber (Corning Costar Cor­
poration). Total bone marrow or CD11b+ purified cells (2 × 105/100 µl) 
were seeded in the upper chamber, whereas in the lower chamber 600 µl of 
medium (RPMI 0.5% BSA) containing 15 µM 22R­HC or 22S­HC or 100 ng 
CXCL5, CXCL12, CCL3, or IL­8. 2 h later, migrated cells were measured by 
flow cytometer acquisition of a fixed number of beads (10,000/sample; Poly­
sciences). GPCR involvement was investigated by pretreating the cells for 
90 min at 37°C with 500 ng PTX. Desensitization experiments were per­
formed by pretreating the cells for 30­45 min at room temperature with 
50 µM 22R­HC or 2 µg/ml CXCL5. 500 ng PTX B­Oligomer was used as 
control of PTX inhibition. Experiments with SB225002 were performed 
treating the cells with 20 µM SB225002 before migration. Results of migra­
tion experiments were calculated as described previously (Villablanca et al., 
2010). Spontaneous migration was always subtracted with the exception of 
the experiments reported in Fig. 2 (C and D).
Analysis of tumor-infiltrating cells. RMA­Mock, RMA­SULT2B1b, 
LLC­Mock, and LLC­SULT2B1b tumors have been described previously 
(Villablanca et al., 2010). AB1­Mock and AB1­SULT2B1b were obtained by 
engineering AB1 cells with lentivirus encoding SULT2B1b or empty vector 
as described previously (Villablanca et al., 2010). Tumors collected 14–15 d 
after injection were cut into small fragments and digested for 45­60 min at 
37°C with 1.4 mg/ml collagenase A, B, and D (Roche) and 40 µg/ml DNase 
(Roche) mixture in RPMI medium with 10% FBS. Single cell suspensions 
were washed and labeled with Dead Cell Stain kit reagents for 30 min at 4°C. 
After washing, the cells were incubated for 5 min at RT with Fc­blocking 
solution (10 µg/ml mouse Fc Block; BD) and labeled with CD11b, Gr1, 
CD45.1, or CD45.2 mAbs. Samples were run by FACSCalibur flow cytom­
eter (BD) and analyzed by FlowJo software gating on live cells. 10 µM 22R­
HC or 22S­HC were administered every 2 d intratumor. After 14 d, collected 
cells were analyzed as described above.
Real-time RT-PCR experiments. Myeloid cells (immature and mature) 
were purified by percoll gradients from bone marrow of wild­type mice, 
or mice injected with RMA­Mock­ or RMA­SULT2B1b. Total RNA 
was isolated with TRIZOL (Invitrogen). Reverse transcription was per­
formed from 1–2 µg of total RNA, using MLV­reverse transcription (In­
vitrogen). qRT­PCR was performed using real­time PCR (ABI PRISM 
7900; Applied Biosystems) and Sybr Green. The comparative Ct method 
was used to quantify transcripts normalized to cyclophillin as a gene refer­
ence. qRT­PCR was performed using primers specific for the LXR target 
genes Abcg1 and Srebp-1c. Primers for Bv8 have been reported in Shojaei 
et al. (2007b). Primers for Cyp11a1, Cyp27a1, and Ch25h are as follows: 
Cyp11a1 forward, 5­AGAGTTTCCAAAAGTATGGCCC­3; reverse, 
5­ATACTGGTGATAGGCCACCCAGG­3. Cyp27a1 forward, 5­GAC­
CTCCAGGTGCTGAAC­3; reverse 5­CTCCTGTCTCATCACTTG­
CTC­3. Ch25h forward, 5­CTGCCTGCTGCTCTTCGACA­3; reverse, 
5­CCGACAGCCAGATGTTAATC­3.
In vivo migration experiments. We injected NOD­SCID mice with 
RMA­Mock or RMA­SULT2B1b. 13–14 d later, we transferred 10 × 106 
CFSE­labeled total bone marrow cells into tumor­bearing mice. 18 h later, 
tumors were processed as described before. The percentage and number of 
bone marrow–derived exogenous and endogenous CD11bhighGr1high cells 
was evaluated by gating on CFSE+ and CD45.1+ cells, respectively.
Parabiosis experiments. 6–8­wk­old sex­matched congenic C57BL/6 
wild­type mice were joined at the flanks as described in Wright et al. (2001). 
3 d later, 5 × 105 RMA cells were injected s.c. in the flank of the CD45.2 
mice. Mice were surgically separated 7, 4, and 2 d prior to collection of 
tumors and analysis.
Immunofluorescence, immunohistochemistry, and immunocyto-
chemistry. For immunofluorescence, we used anti–CD11b­FITC, biotinyl­
ated anti­Gr1 antibody revealed by streptavidin, Alexa Fluor 555 (Invitrogen), 
and DAPI. We embedded samples in OCT freezing medium and prepared 
tissue sections 7 mm thick, which were then fixed in 4% paraformaldehyde. 
Images were taken by the Eclipse i80 microscope (Nikon). For immuno­
histochemistry, tumor samples were embedded in optimal cutting tempera­
ture medium and frozen in liquid nitrogen. We stained 3­µm paraffin sections 
with H&E for morphological analysis or immunostained them with rat anti­
CD31 mAb (Serotec), followed by a biotinylated conjugated rat­specific 
antibody (Biocare). Reactions were visualized with horseradish peroxidase–
conjugated streptavidin and 3,3 diaminobenzidine as chromogen (Biogenex). 
Slides from LXR ligand migrating CD11bhighGr1high cells were prepared by 
centrifugation at 1,500 rpm for 10 min in a Shandon Cytospin 3. Cells were 
stained using May­Grunwald­Giemsa and evaluated under light microscopy.
Matrigel plug assays. 300 µl matrigel containing 0.5 mM 22R­HC or 
0.5 mM 22S­HC (100 µl) was injected subcutaneously into C57BL/6 mice. 
Plugs were removed after 5 h, digested for 1 h at 37°C with 1.8 U/ml Dip­
sase (Gibco), and analyzed by FACS as described above. 0.8 mM SB225002 
was given intraperitoneally 2 d before matrigel injection. Matrigel contain­
ing CXCL5, 22R­HC, or 22S­HC alone or together with blocking anti­
bodies against mouse CXCL1, CXCL3, CXCL5, and CXCL7 chemokines 
(R&D Systems; 10 µg each) was injected subcutaneously into C57BL/6 
mice. 5 h later, plugs were removed and analyzed as described above.
CXCL1 and CXCL5 ELISA assays. 7­d­established RMA­Mock and 
RMA­SULT2B1b tumors were collected and digested mechanically and en­
zymatically up to single cell suspension. Cells were counted and plated in 24­
well plates (106 cells/well in 1 ml). After 24 h, supernatants were collected 
and the content of CXCL1 and CXCL5 was measured according to the 
manufacturer’s recommendations. CXCL1 and CXCL5 ELISA kits were 
from R&D Systems.
Viral vectors and transduction procedures. The mCXCR2­NGFr 
lentiviral transfer vector was generated by cloning the murine CXCR2 
cDNA in place of the GFP into the self­inactivating hPGK.GFP.wPRE.
mhCMV.NGFr.SV40PA lentiviral vector (AgeI–SalI sites). Concentrated 
VSV­G–pseudotyped LV stocks were produced and titred as described previ­
ously (Villablanca et al., 2010). L1.2 cells were transduced with 108 or 109 
transduction units (TU)/ml VSV­G–pseudotyped LV stocks, corresponding 
to 1.5 or 15 MOI (Villablanca et al., 2010).
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Down-regulation of CXCR2. CD11b+ cells were treated with 50 µM of 
22R­HC or 22S­HC, 2 µg/ml CXCL5, 1 µg/ml SDF­1, or 10 µM 
SB225002 for 30 min at room temperature. After washing, the cells were 
labeled with anti­CD11b, anti­Gr1, and anti­CXCR2 mAbs and run 
by FACS.
35S-GTPS binding assay. Mock­ or CXCR2­transduced L1.2 cells were 
homogenized in 5 mM Tris–HCl and 2 mM EDTA, pH 7.4, and centrifuged 
at 48,000 g for 15 min at 4°C. The resulting pellets (plasma membranes) were 
washed in 50 mM Tris–HCl and 10 mM MgCl2, pH 7.4, and stored at 
80°C until use. The assay was performed as described in de Kruijf et al. 
(2011) with minor modifications. In brief, aliquots of control or 10 µg 
CXCR2­expressing membranes were incubated in 96­well plates in assay 
buffer (20 mM Hepes, 3 mM MgCl2, and 100 mM NaCl, pH 7.4) supple­
mented with 3 µM GDP, 0.15 nM 35S­GTPS (1,250 Ci/mmol; Perkin 
Elmer), and different compound concentrations (10–50 µM). 0.1–50 nM of 
the CXCR2 agonist IL­8 was also assayed in parallel as a reference com­
pound. SB225002 antagonist was added for 5 min before the addition of IL­8 
or 22R­HC to determine the inhibition of the agonist­mediated G protein 
activation. After incubation at room temperature in a shaking water bath for 
60 min, cells were harvested by rapid filtration and assayed for 35S radioactiv­
ity. Nonspecific 35S­GTPS binding was measured with 50 µM GTPS. 
Analysis and graphic presentation of 35S­GTPS binding data were obtained 
by a nonlinear multipurpose curve fitting computer program (Prism; Graph­
Pad Software).
Measurement of cAMP levels. Intracellular cAMP levels were measured 
using a competitive binding method (Daniele et al., 2011). In brief, mock­ or 
CXCR2­transduced CHOK1 cells were seeded on 24­well plates (48 × 103 
cells/well) in 0.5 ml of medium. After 24 h, the entire medium was removed, 
and the cells were incubated at 37°C for 15 min with 0.4 ml DMEM in the 
presence of 20 µM of the phosphodiesterase inhibitor 4­[(3­butoxy­4­ 
methoxyphenyl)­methyl]­2­imidazolidinone (Ro20­1724). The dose–response 
curve of tested ligands was evaluated by assessing their ability to inhibit 
cAMP accumulation stimulated by 1 µM forskolin. The compounds were 
added to cells for 15 min. When required, cells were preincubated for 10 min 
with SB225002 antagonist. The reaction was terminated by the removal of 
the medium and the addition of 200 µl of 0.4 N HCl. After 30 min, lysates 
were neutralized with 50 µl 4 N KOH, and the suspension was centrifuged 
at 800 g for 5 min. For the determination of cAMP production, the cAMP 
binding protein was incubated with 2 nM [3H]cAMP and 50 µl of cell lysate 
or cAMP standard (0–16 pmol) at 0°C for 150 min in a total volume of 
300 µl. The bound radioactivity was separated by rapid filtration through 
GF/C glass fiber filters (PerkinElmer Life and Analytical Sciences) and 
washed twice with 4 ml of 50 mM Tris­HCl, pH 7.4. The radioactivity was 
measured by liquid scintillation spectrometry.
Receptor binding assay. Competition for the binding of 125I­labeled IL­8 
([125I]IL­8; sp. act., 2,200 Ci/mmol; Perkin Elmer) to mouse L1.2 cells was 
conducted as described previously (Sozzani et al., 1997). Mock­ or CXCR2­
transduced L1.2 cells (0.8 × 106/50 µl) in binding medium (RPMI 1640 
with 1 mg/ml BSA) were incubated with 0.3 nM of labeled chemokine in 
the presence of 300 nM of unlabeled IL­8 or 100 µM 22R­HC, 25­HC, 
22S­HC, or 4­HC at 4°C for 2 h. Dose­dependent inhibition experiments 
were performed by incubating the cells with 100, 50, 10, or 1 µM 22R­HC 
or 22S­HC. At the end of the incubation, cells were pelleted through a cush­
ion of oil by microcentrifugation. The radioactivity present in the tip of the 
tubes was evaluated using a gamma counter. Nonspecific binding to L1.2 
mock­transduced cells was always subtracted for each condition described.
OT-I proliferation assay. Splenocytes from OT­I mice were labeled with 
4 µM CFSE. Then they were washed and pulsed for 1 h at 37°C with 2 µg/ml 
SIINFEKL peptide. LXR ligand migrating and nonmigrating CD11b+ 
Gr1+ cells (105 or 5 × 104) were cultured in 96­well round­bottomed plates 
with 2 × 105 CFSE­labeled OT­I splenocytes. 105, 5 × 104, and 2.5 × 104 
tumor­infiltrating neutrophils were purified using Ly6G­microbeads (Miltenyi 
Biotec), analyzed by FACS (CD11b+Ly6G+ were >90% of the cells), and 
then cultured in 96­well round­bottomed plates with 2 × 105 CFSE­labeled 
OT­I splenocytes. Cells were analyzed 3 d later with a FACSCalibur flow cy­
tometer with FlowJo software. Data are presented as the percentage of prolif­
eration of SIINFEKL­pulsed, CFSE­labeled OT­I splenocytes relative to the 
proliferation of SIINFEKL­pulsed, CFSE­labeled OT­I splenocytes alone 
(set as 100%). To test OT­I memory cells, we harvested OT­I splenocytes 
from OT­I mice previously immunized (10 d) with 5 µg SIINFEKL peptide 
emulsified in complete Freund’s adjuvant.
Mouse total MMP-9 and Bv8 assays. 22R­HC migrating and nonmi­
grating cells and fresh splenocytes (2 × 106 cells/ml) were plated in 24­well 
plates. After 24 h, supernatants were collected and the content of total 
MMP­9 was measured according to manufacturer’s recommendations (mouse 
total MMP­9; Quantikine; R&D Systems). For Bv8 ELISA assay, we plated 
22R­HC migrating and nonmigrating cells in 24­well plates (3 × 106 cells/well 
in 1 ml) in the absence or in the presence of RMA­CM. After 24 h, superna­
tants were collected and the content of Bv8 was measured according to man­
ufacturer’s recommendations (Bv8 ELISA kit; Uscn; Life Science! Inc.).
Angiogenesis assay. We injected mice with 2 × 105 RMA or LLC tumor 
cells alone or admixed with either 22R­HC migrating CD11bhighGr1high or 
nonmigrating CD11b+Gr1+ cells (105) resuspended in 100 µl PBS, mixed 
with 100 µl of matrigel. 6 d later, mice were sacrificed and matrigel plugs 
collected and digested with 1.4 mg/ml collagenase A, B, and D and 1.8 U/ml 
Dispase. Cell suspensions were labeled with Dead Cell Stain kit reagents for 
30 min at 4°C. After washing, cells were incubated for 5 min at room tem­
perature with Fc­blocking solution (10 µg/ml mouse Fc Block; BD) and la­
beled with CD31 and CD45 mAbs. We analyzed the samples by FACS 
(Mazzieri et al., 2011) and considered the endothelial cells as DeadCD45 
CD31+ cells. Experiments with B16F1 were performed by injecting 0.5 × 105 
B16F1 cells alone or admixed with 5 × 105 BM­purified neutrophils.
Tumor challenge in wild-type, Cxcr2/, Lxr/, or Lxr/ chi-
mera mice. C57BL/6 mice were injected subcutaneously with 1 × 105 
RMA, 3 × 105 LLC, or intraperitoneally with 3 × 106 AB1 tumor cells. We 
evaluated tumor size by measuring perpendicular diameters by a caliper. For 
AB1 tumors, we evaluated overall survival and the number of peritoneal 
tumor nodules 14 d after tumor inoculation. Data are reported as the mean 
tumor volume ± SEM. We gave 0.8 mM SB225002 (Tocris) or DMSO in­
traperitoneally every 2 d, starting 5 d after tumor infusion. We gave 10 µM 
22R­HC intratumor every 2 d. We transplanted lethally irradiated (11 Gy) 
C57BL/6 mice with bone marrow of Cxcr2/, Lxr/, Lxr/, or WT 
mice (5 × 106 bone marrow cells/mouse). 6–8 wk later, we challenged mice 
with RMA with or without SB225002, or with LLC. Cxcr2/ genotype 
was performed by PCR on splenocytes at the end of the experiments. 
Lxr/ or Lxr/ genotype was performed by PCR on blood cells before 
tumor challenge. Because Cxcr2/ chimera mice underwent death during 
the reconstitution phase, we treated transplanted mice with enrofloxacin for 
15 d (7.5 mg/150 µl Baytril 5% solution in 300 ml of drinking water) ac­
cording to the indication of the veterinary staff of our spf facility.
Neutrophil depletion experiments. C57BL/6 mice were injected subcu­
taneously with RMA (1 × 105). 7 d later, we performed neutrophil depletion 
by intratumor injections of 30 µg of purified anti­Ly6G antibody 1A8 (Bio­
Legend) or rat IgG control antibody (Jackson ImmunoResearch Laborato­
ries, Inc.) twice per week, as described in Fridlender et al. (2009). Tumor 
neutrophil depletion and angiogenesis were evaluated at the end of the tumor 
challenge by flow cytometry using anti­CD11b, anti­Gr1, anti­CD31, and 
anti­CD45 mAbs. Tumor growth was analyzed as described above.
Statistical analysis. Data are expressed as mean ± SEM and were analyzed 
for significance by ANOVA with Dunnet’s, Bonferroni’s, or Tukey’s multi­
ple comparison test, or by Student’s t test. The analysis was performed with 
Prism software.
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Online supplemental material. Fig. 1 shows the morphological and phe­
notypic characterization of gated 22R­HC migrating and nonmigrating 
CD11b+Gr1+ cells. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20130440/DC1.
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